We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zoetis (ZTS) Stock Sinks As Market Gains: Here's Why
Read MoreHide Full Article
Zoetis (ZTS - Free Report) ended the recent trading session at $69.10, demonstrating a -1.05% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.2%. Elsewhere, the Dow gained 0.04%, while the tech-heavy Nasdaq added 0.04%.
Shares of the animal health company witnessed a loss of 8.32% over the previous month, trailing the performance of the Medical sector with its loss of 1.75%, and the S&P 500's loss of 0.35%.
Analysts and investors alike will be keeping a close eye on the performance of Zoetis in its upcoming earnings disclosure. The company's earnings report is set to go public on November 5, 2026. The company is forecasted to report an EPS of $1.52, showcasing a 10.59% downward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $2.31 billion, down 3.66% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of $6.2 per share and revenue of $9.24 billion, which would represent changes of -3.28% and -2.45%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Zoetis. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. At present, Zoetis boasts a Zacks Rank of #5 (Strong Sell).
With respect to valuation, Zoetis is currently being traded at a Forward P/E ratio of 11.26. This signifies a discount in comparison to the average Forward P/E of 16.38 for its industry.
We can additionally observe that ZTS currently boasts a PEG ratio of 1.63. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As the market closed yesterday, the Medical - Drugs industry was having an average PEG ratio of 1.73.
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 176, which puts it in the bottom 29% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Zoetis (ZTS) Stock Sinks As Market Gains: Here's Why
Zoetis (ZTS - Free Report) ended the recent trading session at $69.10, demonstrating a -1.05% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.2%. Elsewhere, the Dow gained 0.04%, while the tech-heavy Nasdaq added 0.04%.
Shares of the animal health company witnessed a loss of 8.32% over the previous month, trailing the performance of the Medical sector with its loss of 1.75%, and the S&P 500's loss of 0.35%.
Analysts and investors alike will be keeping a close eye on the performance of Zoetis in its upcoming earnings disclosure. The company's earnings report is set to go public on November 5, 2026. The company is forecasted to report an EPS of $1.52, showcasing a 10.59% downward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $2.31 billion, down 3.66% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of $6.2 per share and revenue of $9.24 billion, which would represent changes of -3.28% and -2.45%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Zoetis. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. At present, Zoetis boasts a Zacks Rank of #5 (Strong Sell).
With respect to valuation, Zoetis is currently being traded at a Forward P/E ratio of 11.26. This signifies a discount in comparison to the average Forward P/E of 16.38 for its industry.
We can additionally observe that ZTS currently boasts a PEG ratio of 1.63. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As the market closed yesterday, the Medical - Drugs industry was having an average PEG ratio of 1.73.
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 176, which puts it in the bottom 29% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.